IX Biopharma    Last:0.355    +0.01

iX Biopharma

bb cant wait liao, 40 easily hit

tofudidi      ( Date: 13-Apr-2026 14:21) Posted: wait for 40c to come. may see it this week or even later closing. very strong buy.  SmallSmall      ( Date: 13-Apr-2026 14:16) Posted: Gemini AI iX Biopharma (SGX:42C) is currently experiencing a significant re-rating, with its stock price surging  +7.58% today, 13 April 2026, to  S$0.355.  This momentum follows a landmark research report from  Phillip Securities  on 10 April 2026, which issued a  S$1.00 target price&mdash nearly 3x the current trading level&mdash highlighting the stock as a " Year of the Unicorn" pick.    Financial Snapshot   IX Biopharma Ltd (42C) $0.355   7.58% today As of 13 Apr, 2:15  pm SGT  &bull   Disclaimer   9:00  am11:00  am1:00  pm0.320.340.36 Prev close $0.33 13 Apr 2026 9:00  am - 2:15  pm     Key Inflection Points DoD Validation & Funding: In February 2026, iX Biopharma secured a  US$41 million contract  from the  US Department of Defense (DoD)  to fully fund the Phase 3 clinical development of its lead drug,  Wafermine. Near-Term Revenue Pathways: Emergency Use Authorisation (EUA): The DoD funding supports an EUA pathway, potentially allowing immediate sale and battlefield deployment of Wafermine as early as  1Q 2027, ahead of full FDA approval. US Compounding Pharmacy: A recent joint venture with US-based Orion Specialty Labs provides entry into the world' s largest compounding pharmacy market. Grant Inflows: Non-dilutive grant funding from the DoD provides immediate capital without further shareholder dilution. Late-Stage Progress: Wafermine has completed Phase 2b trials with strong results, and the DoD' s " sole-source" procurement indicates they view iX Biopharma as uniquely capable of delivering this non-opioid pain solution. Improving Fundamentals: The company reduced its net loss by  67% year-on-year  for 1H FY2026 and successfully upsized a private placement to  S$15 million  due to strong institutional demand.  www.theedgesingapore.com  +8       Analyst Outlook Phillip Securities  values the company at  S$1.00 per share  using a sum-of-the-parts (SOTP) approach, even after applying a  40% discount  to the net present value of Wafermine to account for clinical risks. Analysts see multiple exit or monetisation routes, including full commercial launch, out-licensing, or an outright sale of the asset.  Would you like to see a  detailed breakdown  of the Wafermine Phase 2b clinical results or more info on the  compounding pharmacy joint venture?

 

wait for 40c to come. may see it this week or even later closing. very strong buy. 

SmallSmall      ( Date: 13-Apr-2026 14:16) Posted: Gemini AI iX Biopharma (SGX:42C) is currently experiencing a significant re-rating, with its stock price surging  +7.58% today, 13 April 2026, to  S$0.355.  This momentum follows a landmark research report from  Phillip Securities  on 10 April 2026, which issued a  S$1.00 target price&mdash nearly 3x the current trading level&mdash highlighting the stock as a " Year of the Unicorn" pick.    Financial Snapshot   IX Biopharma Ltd (42C) $0.355   7.58% today As of 13 Apr, 2:15  pm SGT  &bull   Disclaimer   9:00  am11:00  am1:00  pm0.320.340.36 Prev close $0.33 13 Apr 2026 9:00  am - 2:15  pm     Key Inflection Points DoD Validation & Funding: In February 2026, iX Biopharma secured a  US$41 million contract  from the  US Department of Defense (DoD)  to fully fund the Phase 3 clinical development of its lead drug,  Wafermine. Near-Term Revenue Pathways: Emergency Use Authorisation (EUA): The DoD funding supports an EUA pathway, potentially allowing immediate sale and battlefield deployment of Wafermine as early as  1Q 2027, ahead of full FDA approval. US Compounding Pharmacy: A recent joint venture with US-based Orion Specialty Labs provides entry into the world' s largest compounding pharmacy market. Grant Inflows: Non-dilutive grant funding from the DoD provides immediate capital without further shareholder dilution. Late-Stage Progress: Wafermine has completed Phase 2b trials with strong results, and the DoD' s " sole-source" procurement indicates they view iX Biopharma as uniquely capable of delivering this non-opioid pain solution. Improving Fundamentals: The company reduced its net loss by  67% year-on-year  for 1H FY2026 and successfully upsized a private placement to  S$15 million  due to strong institutional demand.  www.theedgesingapore.com  +8       Analyst Outlook Phillip Securities  values the company at  S$1.00 per share  using a sum-of-the-parts (SOTP) approach, even after applying a  40% discount  to the net present value of Wafermine to account for clinical risks. Analysts see multiple exit or monetisation routes, including full commercial launch, out-licensing, or an outright sale of the asset.  Would you like to see a  detailed breakdown  of the Wafermine Phase 2b clinical results or more info on the  compounding pharmacy joint venture?

 

Maybe other short but not me. No time monitor

goldenpiggy      ( Date: 13-Apr-2026 14:07) Posted: then after that another round of shorting..... piscesmonkey      ( Date: 13-Apr-2026 14:02) Posted: More likey short cove

 

• DoD Validation & Funding: In February 2026, iX Biopharma secured a  US$41 million contract  from the  US Department of Defense (DoD)  to fully fund the Phase 3 clinical development of its lead drug,  Wafermine.
• Near-Term Revenue Pathways:
  • Emergency Use Authorisation (EUA): The DoD funding supports an EUA pathway, potentially allowing immediate sale and battlefield deployment of Wafermine as early as  1Q 2027, ahead of full FDA approval.
  • US Compounding Pharmacy: A recent joint venture with US-based Orion Specialty Labs provides entry into the world' s largest compounding pharmacy market.
  • Grant Inflows: Non-dilutive grant funding from the DoD provides immediate capital without further shareholder dilution.
• Late-Stage Progress: Wafermine has completed Phase 2b trials with strong results, and the DoD' s " sole-source" procurement indicates they view iX Biopharma as uniquely capable of delivering this non-opioid pain solution.
• Improving Fundamentals: The company reduced its net loss by  67% year-on-year  for 1H FY2026 and successfully upsized a private placement to  S$15 million  due to strong institutional demand. 
  www.theedgesingapore.com  +8

 

Who are biting the 355? 360-370 fake sell queues?

Stocky901      ( Date: 13-Apr-2026 14:08) Posted: Clearing 36c now .should be all the way to hit 40c .. ✌ ️

 

iX Biopharma is still trading at a heavily discounted valuation despite being at a clear inflection point, with US Department of Defense-backed funding, late-stage progress of its lead drug Wafermine, and multiple near-term revenue pathways already emerging. As clinical milestones are delivered and the market starts pricing in real commercial potential rather than early-stage risk, the stock could undergo a significant re-rating toward analyst fair value

Today&rsquo s price may represent a rare early-entry opportunity before institutional recognition drives it higher. 

 

Clearing 36c now .should be all the way to hit 40c .. ✌ ️

 

then after that another round of shorting.....

piscesmonkey      ( Date: 13-Apr-2026 14:02) Posted: More likey short cover JurongW      ( Date: 13-Apr-2026 13:59) Posted: Very impressive, buyers come in to push up share price. Now it shows a hammer. It was ice cream pattern in the morning

 

More likey short cover

JurongW      ( Date: 13-Apr-2026 13:59) Posted: Very impressive, buyers come in to push up share price. Now it shows a hammer. It was ice cream pattern in the morning. SmallSmall      ( Date: 13-Apr-2026 13:55) Posted: $0.35 clear ! You say leh? Shortists die round

 

Digesting 355-360, can 365 hold?

JurongW      ( Date: 13-Apr-2026 13:59) Posted: Very impressive, buyers come in to push up share price. Now it shows a hammer. It was ice cream pattern in the morning. SmallSmall      ( Date: 13-Apr-2026 13:55) Posted: $0.35 clear ! You say leh? Shortists die round

 

Very impressive, buyers come in to push up share price.
Now it shows a hammer. It was ice cream pattern in the morning.

SmallSmall      ( Date: 13-Apr-2026 13:55) Posted: $0.35 clear ! You say leh? Shortists die round 2 JurongW      ( Date: 13-Apr-2026 13:52) Posted: Based on your speciial " gut feel" technical indicator?

 

backside black black

piscesmonkey      ( Date: 13-Apr-2026 13:40) Posted: Cover at 325 no time to monitor liao huat to all

 

I no die hard. 😁

SmallSmall      ( Date: 13-Apr-2026 13:55) Posted: $0.35 clear ! You say leh? Shortists die round 2 JurongW      ( Date: 13-Apr-2026 13:52) Posted: Based on your speciial " gut feel" technical indicator?

 

$0.35 clear ! You say leh? Shortists die round 2

JurongW      ( Date: 13-Apr-2026 13:52) Posted: Based on your speciial " gut feel" technical indicator?  tofudidi      ( Date: 13-Apr-2026 13:51) Posted: same style as MT last time. 30c nobody wanna touch. after that skyrocket to $1-$2 range

 

Based on your speciial " gut feel" technical indicator? 

tofudidi      ( Date: 13-Apr-2026 13:51) Posted: same style as MT last time. 30c nobody wanna touch. after that skyrocket to $1-$2 range

 

same BB

tofudidi      ( Date: 13-Apr-2026 13:51) Posted: same style as MT last time. 30c nobody wanna touch. after that skyrocket to $1-$2 range

 

same style as MT last time. 30c nobody wanna touch. after that skyrocket to $1-$2 range

 

Its ATH was about 49.  How did u arrive at 60?  Care to share your analysis?

Sgvale      ( Date: 13-Apr-2026 13:43) Posted: At least 0.60 JurongW      ( Date: 13-Apr-2026 13:02) Posted: How much upside are u looking at ?  Based on FA , TA

 

40c next hurdle. strong target price $1

 

hahaha.. very good deal liao weak hands all out liao. left the strong hands

piscesmonkey      ( Date: 13-Apr-2026 13:40) Posted: Cover at 325 no time to monitor liao huat to all